Skip to main content

Table 4 All-cause ESKD-associated variants at P < 5 × 10–6 in baseline model

From: Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

Lead variant

CHR

POS

Locus

Effect/other alleles

Info

Stage 2 (3432 T2D-ESKD cases vs. 6977 non-diabetic non-nephropathy controls)

Stage 4 (1910 non-diabetic ESKD cases vs. 908 non-diabetic non-nephropathy controls)

Stage 5: Meta-analysis (5342 all-cause ESKD cases vs. 6977 non-diabetic non-nephropathy controls)

EAF

OR (95% CI)

P

EAF

OR (95% CI)

P

EAF

OR (95% CI)

P

HetP

rs76971802

3

188607071

LPP

T/C

0.95

0.087

1.35 (1.19,1.54)

8.66E−06

0.084

1.42 (1.08,1.87)

0.013

0.087

1.35 (1.2,1.52)

1.36E−06

0.86

rs5863506

4

162909217

FSTL5

TA/T

0.96

0.33

1.22 (1.12,1.32)

1.64E−06

0.33

1.19 (1.01,1.40)

0.033

0.33

1.21 (1.12,1.30)

4.57E−07

0.87

rs141746998

8

54310938

OPRK1/ATP6V1H

CAT/C

0.94

0.031

0.62 (0.5,0.76)

9.40E−06

0.034

0.61 (0.39,0.93)

0.022

0.031

0.61 (0.5,0.75)

1.44E−06

0.96

rs11997465

8

110891977

SYBU/KCNV1

C/G

0.99

0.28

1.22 (1.12,1.33)

3.21E−06

0.28

1.21 (1.02,1.43)

0.026

0.28

1.22 (1.13,1.31)

6.72E−07

0.65

rs77113398

13

107103906

EFNB2

A/G

0.93

0.023

1.94 (1.52,2.47)

1.25E−07

0.021

1.87 (1.08,3.24)

0.025

0.023

1.94 (1.55,2.43)

9.84E−09

0.96

rs9622363

22

36656555

APOL1

A/G

0.95

0.45

0.77 (0.72,0.84)

1.42E−10

0.35

0.42 (0.36,0.48)

4.32E−29

0.43

0.68 (0.64,0.73)

1.96E−25

1.14E−09

  1. Baseline model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were included
  2. Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence interval, P, P value, Info average imputation quality, HetP heterogeneity P value